Alnylam Reports Additional Interim Phase 1 Results For ALN-APP, In Development For Alzheimer's Disease And Cerebral Amyloid Angiopathy
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals (NASDAQ:ALNY) has reported positive interim results for the Phase 1 study of ALN-APP, a treatment for Alzheimer's disease and cerebral amyloid angiopathy (CAA). The study showed sustained pharmacodynamic activity up to 10 months after administration and marked reductions in Aβ42 and Aβ40, amyloid fragments implicated in Alzheimer's disease and CAA. The first patient has been dosed in the multiple-dose Part B portion of the study, which is proceeding in Canada, UK, and the Netherlands. The study remains on partial clinical hold in the U.S. due to findings observed in non-clinical chronic toxicology studies.
October 25, 2023 | 3:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals has reported positive interim results for the Phase 1 study of ALN-APP, a treatment for Alzheimer's disease and CAA. The study remains on partial clinical hold in the U.S. due to findings observed in non-clinical chronic toxicology studies.
The positive interim results for the Phase 1 study of ALN-APP are likely to boost investor confidence in Alnylam Pharmaceuticals. However, the partial clinical hold in the U.S. could potentially limit the market for the treatment and may negatively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100